Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 4, 2014, Pages 257-262

  Zanon, Cristina ^a   Stocchero, Matteo ^b   Albiero, Elena ^a,c   Castegnaro, Silvia ^a   Chieregato, Katia ^a   Madeo, Domenico ^c   Rodeghiero, Francesco ^a,c   Astori, Giuseppe ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b S IN Soluzioni Informatiche   (Italy)

^c Fondazione Progetto Ematologia   (Italy)

Author keywords

adoptive immunotherapy; cellular therapy; cytokine induced killer cells; ex vivo expansion; multivariate statistical data analysis

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN;

ARTICLE; CELL EXPANSION; CELL GROWTH; CELL ISOLATION; CONCENTRATION (PARAMETERS); CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CELL CULTURE; CULTURE TECHNIQUE; CYTOLOGY;

CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOKINE-INDUCED KILLER CELLS; HUMANS; MULTIVARIATE ANALYSIS; PHENOTYPE;

EID: 84902539271     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21124     Document Type: Article

References (19)

1. Lu PH, Negrin RS,. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696. (Pubitemid 24251113)
2. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A,. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Exp Opin Biol Ther 2009; 9: 831-840.
3. Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF, Zhang XG,. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010; 16: 6155-6162.
4. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006; 26: 2237-2242. (Pubitemid 43980179)
5. Wu C, Jiang J, Shi L, Xu N,. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008; 28: 3997-4002.
6. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS,. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 181-187. (Pubitemid 40287916)
7. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study. Haematologica 2007; 92: 952-959. (Pubitemid 350144242)
8. Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, Hwang W, Loh Y, Goh YT, Suck G, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012; 47: 957-966.
9. Linn YC, Lau SK, Liu BH, Ng LH, Yong HX, Hui KM,. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2008; 126: 423-435.
10. Sangiolo D,. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2: 363-368.
11. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: Implications for their infusion across major HLA barriers. Int Immunol 2008; 20: 841-848. (Pubitemid 351865860)
12. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS,. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97: 2923-2931.
13. Goncalves R, da Silva CL, Ferreira BS, Lemos MA, Lemos F, Almeida-Porada G, Cabral JM,. Kinetic analysis of the ex vivo expansion of human hematopoietic stem/progenitor cells. Biotechnol Lett 2006; 28: 335-340.
14. Wold S, Kettaneh N, Fridén H, Holmberg A,. Modelling and diagnostics of batch processes and analogous kinetic experiments. Chemometr Intelligent Lab Syst 1998; 44: 331-340. (Pubitemid 29016108)
15. Trygg J, Wold S,. Orthogonal projections to latent structures (O-PLS). J Chemometr 2002; 16: 119-128.
16. Westerhuis J, Hoefsloot HJ, Smit S, Vis D, Smilde A, Velzen EJ, Duijnhoven JM, Dorsten F,. Assessment of PLSDA cross validation. Metabolomics 2008; 4: 81-89. (Pubitemid 351217591)
17. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG,. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011; 137: 305-310.
18. Lahoti V, Murphy W, Al-Rubeai M,. Mathematical approach for the optimal expansion of erythroid progenitors in monolayer culture. J Biotechnol 2012; 161: 308-319.
19. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M,. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009; 37: 616-628.